New Retina Radio By Eyetube

In this opening installment of the New Retina Radio miniseries "International Perspectives," moderator Patricio Schlottmann (Argentina) sits down with panelists Catherine Creuzot-Garcher (France) and Adnan Tufail (United Kingdom) to review their strategies for treating patients with diabetic macular edema. The group discusses government regulations regarding the use of particular therapies and reviews why, in many cases, anti-VEGF therapy is the most effective therapeutic option.  This editorially independent podcast is supported with advertising.

If new treatment options for wet AMD are approved for treatment, retina specialists will have even more options to switch patients to a new therapy. Which drug candidates have phase 3 data and real-world data that could point toward upcoming action by regulatory bodies? Arshad M. Khanani, MD, MA (United States), convenes an international panel comprised of Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to review data related to brolucizumab (Beovu, Novartis), the Port Delivery System with Ranibizumab (Genentech), and faricimab (Roche).  This editorially independent podcast is supported with advertising.

As the threat of COVID-19 subsides, scientists are working to make sense of the information that was gathered during the pandemic. Caroline Baumal, MD, asks M. Ali Khan, MD; Vlad Matei, MD; and Christina Weng, MD, MBA, to tackle two papers that analyze data collected during this time. First, they address the strengths and limits of a paper from the infectious disease realm that used history of AMD as a marker for complement inhibition in patients with COVID-19. Then, they parse the details of an article reviewing how real-world high-frequency patients with wet AMD fared when treatment intervals were increased during the height of the pandemic. This editorially independent podcast is supported with advertising.

Retina specialists around the world aim to reduce treatment burden while maximizing therapeutic outcomes in patients. How do global experts decide when to switch and to which therapy? Arshad M. Khanani, MD, MA (United States), is joined by Justus G. Garweg, MD (Switzerland), Seenu M. Hariprasad, MD (United States), and Peter Kertes, MD, FRCSC (Canada), to discuss tactics for moving wet AMD patients to new therapies or regimens. Also, Prof. Garweg shares a case of a patient who benefited from a new treatment option approved for wet AMD.  This editorially independent podcast is supported with advertising.

In the third episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Carl Awh, MD, and Dante Pieramici, MD, about surgical options for neovascular AMD and how they might be applied in clinical practice. Although some of these options are still in the later stages of development, the panel looks forward to options that may truly change the treatment paradigm for the better. Click here to listen to this and other episodes in this series. This editorially independent podcast is supported with advertising.

In this roundtable moderated by Allen C. Ho, MD, experts in gene therapy discuss the latest data, clinical trial hurdles, and the promise these programs hold for patients being treated for wet AMD. Participants include Robert L. Avery, MD; Peter Campochiaro, MD, PhD; Jeffrey S. Heier, MD; Szilárd Kiss, MD; and Charles Wykoff, MD, PhD. This editorially independent podcast is supported with advertising.

Masks are effective in curbing transmission of COVID-19. But could they also direct bacteria toward the ocular region? Yoshi Yonekawa, MD, hears from two primary study investigators—Ajay Kuriyan, MD, and Jonathan Chang, MD—about their newly published studies, and invites Paula Pecen, MD, to evaluate the studies' designs, findings, and clinical relevance. After the break, all four doctors compare the two papers and review their respective masking protocols. This editorially independent podcast is supported with advertising.

In the second episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Jennifer Lim, MD, and Charlie Wykoff, MD, PhD, about the challenges inherent to finding the best retreatment interval for each patient. The panel also shares thoughts on how clinical trials could be structured to deliver data that would help clinicians understand durability of existing and new and novel treatment options. Click here to listen to this and other episodes in this series. This editorially independent podcast is supported with advertising.

How effective is the use of autologous retina transplant for the treatment of macular holes? Caroline Baumal, MD, moderates a panel comprised of M. Ali Khan, MD; Vlad Matei, MD; and Christina Weng, MD, MBA, during which they summarize and comment on a recent research paper on this subject published in the journal Ophthalmology. After the break, the group discusses which cases are best suited for this technique and discuss tactics for teaching fellows how to perform autologous retinal transplant. This editorially independent podcast is supported with advertising.

In this episode of the Missing Link podcast series, Carl D. Regillo, MD, speaks with Margaret Chang, MD, and David Eichenbaum, MD, about the consequences of missed injection appointments and less than ideal adherence to monitoring among patients with neovascular AMD. Listen in as the experts discuss some of the challenges inherent to treating patients in real-world practice and share insights on strategies for encouraging adherence. This editorially independent podcast is supported with advertising.

C3 is a possible target in patients with geographic atrophy. What do the latest data from ARVO tell us about the safety and tolerability of NGM621, a drug aimed at that point in the complement cascade? David Eichenbaum, MD, sat down with New Retina Radio to review the results of a phase 1 study evaluating NGM621 in patients with geographic atrophy.  Also, Amy Schefler, MD joined the show to review the design, methods, and rationale for the creation of the COOG2, or the second iteration of the Collaborative Ocular Oncology Group. How might the COOG help advance treatment for ocular cancer?  This editorially independent podcast is supported with advertising.

18-month results for GATHER1 look promising, but another pivotal study is still in the works. What else needs to happen for Zimura to become the first FDA-approved therapy for geographic atrophy? New Retina Radio spoke with Veeral Sheth, MD, about what he shared regarding the GATHER1 study at this year’s ARVO meeting. We also spoke with Matthew Starr, MD, about his research on the development of CME following rhegmatogenous retinal detachment surgery. Could his findings help surgeons better understand the risk factors for complication after surgery? This editorially independent podcast is supported with advertising.

The phase 3 TENAYA and LUCERNE trials, which assessed the safety and efficacy of faricimab for wet AMD therapy, have wrapped up. What did the researchers learn? New Retina Radio spoke with Arshad Khanani, MD, MA, about his ARVO presentation on these trials. We also spoke with David Lally, MD, whose ARVO presentation adds new data to the great fluid debates in wet AMD. What did his research team uncover that can inform our understanding of fluid dynamics in these patients?   This editorially independent podcast is supported with advertising.

Need a refresher on Protocol W, the latest study from the DRCR Retina Network? Yoshi Yonekawa, MD, invites VBS members Ajay Kuriyan, MD; Anton Orlin, MD; and Paula Pecen, MD, to review the data from Protocol W and to discuss how the study may change their practice patterns.  This editorially independent podcast is supported with advertising.

In the second part of this two-part series on literature in retinal detachment surgery, moderator Jay Sridhar, MD, is joined by panelists Brian Do, MD; Sabin Dang, MD; and Avni Finn, MD, MBA, to discuss a pair of recently published reports. The panel reviews an article on the outcomes of primary RRD repair with extensive scleral-depressed vitreous and dynamic examination, as well as a report on 360º laser retinopexy during primary vitrectomy with or without scleral buckling for RRD. This editorially independent podcast is supported with advertising.

In the first part of this two-part series reviewing reports from the Primary Retinal Detachment Outcomes Study Group, moderator Jay Sridhar, MD, invites panelists Brian Do, MD; Sabin Dang, MD; and Avni Finn, MD, MBA, to dissect a trio of papers. They discuss the results of studies examining retinal detachment surgery outcomes in phakic and pseudophakic patients. After the break, the panel summarizes and reviews the findings from a report comparing vitrectomy alone to vitrectomy with scleral buckle for retinal detachment with inferior retinal breaks. This editorially independent podcast is supported with advertising.

Early phase data sets are one of the stars of the Angiogenesis, Exudation, and Degeneration annual meeting. Which presentations are worth a second look? John Kitchens, MD, is joined by Nadia Waheed, MD, and Charles Wykoff, MD, PhD, as they share data from their respective presentations showcased at this year’s meeting. After the break, Drs. Kitchens, Waheed, and Wykoff chat what these early phase data could mean for the future of retina care.   This editorially independent podcast is supported with advertising.

Which upcoming therapies will extend duration for patients with wet AMD? John Kitchens, MD, sits down with Diana Do, MD, and Carl Regillo, MD, to hear about their presentations at this year’s Angiogenesis, Exudation, and Degeneration annual meeting. After the break, Drs. Kitchens, Do, and Regillo discuss how the future of wet AMD therapies may alter clinical care for patients undergoing treatment.  This editorially independent podcast is supported with advertising.

Can OCT be used to detect areas at risk for GA progression in patients with intermediate AMD? Yoshihiro Yonekawa, MD, invites Marion Munk, MD, PhD; Lejla Vajzovic, MD; and David Xu, MD, to discuss a paper published by the AREDS2 Group on this topic. They explore the researchers' findings and discuss the clinical implications of the study's results. This editorially independent podcast is supported with advertising.

How close are retina specialists to offering an effective therapy for patients with geographic atrophy secondary to dry AMD? John Kitchens, MD, hears summaries of two talks from Pravin Dugel, MD, and SriniVas Sadda, MD, from this year’s Angiogenesis, Exudation, and Degeneration meeting. After the break, Dr. Kitchens moderates a discussion about the nuances of bringing treatments in this disease to patients.   This editorially independent podcast is supported with advertising.